drugset / Trial / NCT05536427
Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Unknown
24 enrolled
Peking Union Medical College Hospital
Beijing Immupeutics Medicine Technology Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, safety and effects of IPM001 injection on human hepatocellular carcinoma are going to be investigated, IPM001 is a multiple tumor-associated antigen (TAA) and neoantigen/tumor-specific antigen (TSA) sensitized autoimmune cell injection
Timeline
- Start
- 2022-10-01
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPM001 | Cell therapy | — | — |